Shimadzu (7701) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
12 May, 2026Executive summary
Net sales reached ¥560.7B (+4% YoY), setting a record high for the sixth consecutive year, with operating profit, ordinary income, and profit attributable to owners of parent also hitting record highs for the first time in two years.
Operating profit increased 2.8% to ¥73.7B; ordinary profit rose 14.9% to ¥82.8B; profit attributable to owners of parent grew 12.5% to ¥60.5B.
Growth was driven by strong performance in Analytical & Measuring Instruments, Medical Systems, and Aircraft Equipment, with notable contributions from Japan, North America, Europe, and other Asian regions, offsetting declines in China.
Strategic focus included AI integration, recurring business expansion, and new product launches in key domains.
Overseas sales ratio rose to 56.7%, with significant contributions from Europe and other Asian countries.
Financial highlights
Net sales: ¥560.7B (+4% YoY); Operating income: ¥73.7B (+3% YoY); Ordinary income: ¥82.8B (+15% YoY); Profit attributable to owners of parent: ¥60.5B (+13% YoY).
Gross profit increased to ¥250.1B from ¥234.4B YoY; comprehensive income surged 76.2% to ¥86.7B.
Operating margin slightly decreased to 13.1% (-0.2pt YoY); ROE improved to 11.4% (+0.5pt YoY); ROIC decreased to 9.6% (-0.4pt YoY).
R&D expenses: ¥29.1B (+¥0.2B YoY); CAPEX: ¥22.1B (-¥0.8B YoY); Depreciation and amortization: ¥20.4B (+¥0.5B YoY).
Cash and cash equivalents at year-end rose to ¥160.8B, up ¥23.6B; EPS increased to ¥209.39.
Outlook and guidance
FY2026 guidance projects sales of ¥575.0B (+3% YoY) and OP of ¥76.0B (+3% YoY), aiming for record highs despite uncertainties in the Middle East and global risks.
Ordinary profit expected at ¥75.0B (-9% YoY); Net profit at ¥55.0B (-9% YoY).
R&D expenses to rise to ¥30.5B (+¥1.4B YoY); CAPEX to ¥25.0B (+¥2.9B YoY).
Annual dividend projected to rise to ¥70 per share, marking the 13th consecutive increase.
Tescan's performance not included in guidance as transaction closing is pending.
Latest events from Shimadzu
- Record sales and profit growth, with sales guidance raised but profit guidance unchanged.7701
Q3 20265 Feb 2026 - Record H1 sales and profit, with upward guidance and strong AMI/AE performance.7701
Q2 202610 Nov 2025 - Record Q1 sales and profit, but net profit dropped 20.7% amid FX and global risks.7701
Q1 20267 Aug 2025 - Net sales up 7.1%, but operating profit fell 17% on higher costs and China weakness.7701
Q1 202513 Jun 2025 - Record sales and segment growth prompt upward revision of full-year outlook.7701
Q2 202513 Jun 2025 - Record sales streak continues, but profit outlook dims amid tariff and FX headwinds.7701
Q4 20256 Jun 2025 - Record sales growth offset by lower profit from increased investments.7701
Q3 20255 Jun 2025